Search Results
Your search for ,USE matches 11256 pages
Showing 7151 - 7200The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research
Earlier this year, Sean Parker, the cofounder of the music streaming service Napster and an early president of Facebook, joined a growing list of entrepreneurs who are committing large portions of their wealth to funding cancer research. In April, Mr. Parker announced he was donating $250 million...
Neoadjuvant Chemotherapy in High-Risk Soft-Tissue Sarcoma: A New Standard?
For the first time, a randomized trial has provided good evidence to support the use of neoadjuvant chemotherapy for treatment of high-risk soft-tissue sarcoma of the extremities or trunk wall.1 But the findings of the study were surprising, because neoadjuvant chemotherapy with one-size-fits-all...
Expert Point of View: Sandro Pignata, MD
“This study represents a significant step forward in the treatment of recurrent ovarian cancer,” stated formal discussant Sandro Pignata, MD, of the IRCCS National Cancer Institute “Fondazione G. Pascale,” Naples, Italy. He highlighted some key factors: Patients selected for the study were those...
Optimizing Allogeneic Stem Cell Transplantation in Myelofibrosis
Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment for myelofibrosis. The ASCO Post asked an expert in this field, Ayalew Tefferi, MD, how and when he uses stem cell transplant in myelofibrosis, which is a topic he outlined in greater detail in the...
Recent Progress and Concepts in Pancreatic Cancer
November is National Pancreatic Cancer Awareness Month, the impetus for this article. Pancreatic cancer is a huge health challenge. It's the eighth most common cancer in the United States and the fourth most common cause of cancer deaths but is expected to become the second most common cause of...
Another Step Forward for Genomic Assays in Early-Stage Breast Cancer: Findings With MammaPrint in the MINDACT Trial
Genomic assays have had a powerful influence on the management of early-stage breast cancer, particularly estrogen receptor–positive tumors. The mainstay of adjuvant treatment for early-stage, hormone receptor–positive breast cancer has been endocrine therapy, either with tamoxifen and an...
Pembrolizumab as First-Line Therapy in Metastatic NSCLC: Practice-Changing Implications of KEYNOTE-024 Trial
We are in the midst of a paradigm shift in lung cancer. In the past 2 years, the anti–programmed cell death protein 1 (anti–PD-1) inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) were found to improve overall survival in the second-line setting compared with docetaxel for patients with...
Update on Neoplastic Hematology: Review of Recent Clinical Trials
Here is a brief look at the study findings and clinical implications of several recent and important clinical trials in neoplastic hematology. Attention is focused on myelodysplastic syndromes, multiple myeloma, and chronic lymphocytic leukemia. Myelodysplastic Syndromes Clinical Trial:...
‘Exceptional Response’ to First-Line Vismodegib Reported in Patient With Unresectable/Multifocal Adult Medulloblastoma
In a case report in Cancer Biology & Therapy, Lou et al described an exceptional response to first-line treatment with the hedgehog inhibitor vismodegib (Erivedge) in a 51-year-old patient with a history of basal cell carcinoma who was diagnosed with an unresectable/multifocal form of adult...
SITC Publishes First Kidney Cancer Treatment Guideline to Focus on Immunotherapy
The first evidence-based consensus statement on cancer immunotherapy for the treatment of patients with the most common type of kidney cancer, renal cell carcinoma, has been published by the Society for Immunotherapy of Cancer (SITC) in the Journal for ImmunoTherapy of Cancer by Rini et al. The...
Study Describes Genetic Model of Pro-B ALL
After nearly 2 decades of unsuccessful attempts, researchers from the University of Chicago Medicine and the Cincinnati Children's Hospital Medical Center have created the first mouse model for the most common form of infant leukemia. Their discovery, reported by Lin et al in Cancer Cell, could...
NAALADL2 Marker for Aggressive Prostate Cancer May Also Serve as a Drug Target
Researchers have discovered that a marker found on aggressive prostate cancer cells could also be used as a way to guide treatments to the cancer, according to new research presented by Luxton et al at the 2016 National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, United...
NCCN Challenges Medical Community to ‘Just Bag It’ to Eradicate Deadly Medical Error
As part of its mission to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives, the National Comprehensive Cancer Network® (NCCN®) has announced the launch of Just Bag It: The NCCN Campaign for Safe Vincristine...
Do Cancer Survivors Use Medications for Anxiety and Depression at a Higher Rate Than Those Without Cancer?
In a study of population-based data reported in the Journal of Clinical Oncology, Hawkins et al found that adult cancer survivors receive medication for anxiety and depression at twice the rate of that in adults without cancer. The study involved data from the National Health Interview Survey for...
Impact of Neoadjuvant Therapy on Survival in Resectable Pancreatic Cancer
In a propensity score–matched analysis of National Cancer Database data reported in the Journal of Clinical Oncology, Mokdad et al found that neoadjuvant therapy followed by resection was associated with a survival benefit vs upfront resection. Patricio M. Polanco, MD, of the Division of Surgical...
Study Suggests Benefit of Adjuvant Radiation Therapy but Not Chemotherapy in Some Patients With Merkel Cell Carcinoma
In an analysis of National Cancer Data Base data reported in the Journal of the National Cancer Institute, Shailender Bhatia, MD, of the University of Washington/Fred Hutchinson Cancer Research Center, and colleagues found that adjuvant radiotherapy was associated with a survival benefit in...
Higher Baseline Metabolic Tumor Volume and Poorer Outcomes in Patients With High Tumor Burden Follicular Lymphoma
In a pooled analysis reported in the Journal of Clinical Oncology, Michel Meignan, MD, PhD, of the Université Paris-Est Créteil, and colleagues found that higher baseline total metabolic tumor volume measured by 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography–computed tomography (FDG...
Expect Questions About Medical Marijuana
“Whether or not individual professionals support the clinical use of herbal cannabis, all clinicians will encounter patients who elect to use it and therefore need to be prepared to advise them on cannabis-related clinical issues despite limited evidence to guide care,” according to a recently...
Medical Marijuana: The Topic You Can’t Escape
With reports about new marijuana dispensaries sprouting up as more states approve the legal use of medical marijuana, and patients and family members questioning how to get it, medical marijuana is a “topic you can’t escape,” noted Judith A. Paice, PhD, RN.1 Dr. Paice is Director of the Cancer...
Resuscitation During Surgery
During the 1890s, aseptic principles were extended only to the operative area of the patient, not the surgeon, although some surgeons did advocate the use of special white or colored uniforms, and hand washing had already been established. In 1895, just 7 years after Arpad Gerster, MD, published...
ASH Honors Thalia Papayannopoulou, MD, With Wallace H. Coulter Award for Lifetime Achievement in Hematology
The American Society of Hematology (ASH) will recognize Thalia Papayannopoulou, MD, of the University of Washington, Seattle, with the 2016 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Papayannopoulou will be honored for her innovative contributions to cutting-edge areas of ...
Low Vitamin D Levels May Be Linked to Increased Risk of Bladder Cancer
Vitamin D deficiency may be associated with an increased risk of developing bladder cancer, according to a systematic review of seven studies presented at the Society for Endocrinology Annual Conference in Brighton, United Kingdom. Though further clinical studies are needed to confirm the findings, ...
Modified Indication for Erlotinib in Advanced Non–Small Cell Lung Cancer
On October 18, 2016, the indication for erlotinib (Tarceva) in the treatment of non–small cell lung cancer (NSCLC) was modified to limit use to patients with tumors with specific epidermal growth factor receptor (EGFR) mutations in maintenance or second- or greater-line treatment; these mutations...
Diagnosing and Managing Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy is a common side effect of cancer treatment—the incidence is reported to be as high as 70% in the first month of chemotherapy1—and can cause significant disability in patients. The extent of the neurotoxicity incurred by patients varies depending on the...
Forging Collaboration Between Children’s and Adult Oncology Groups in Designing Trials for Adolescents and Young Adults
Nonrhabdomyosarcoma soft-tissue sarcomas account for about 5% of all childhood malignancies and are also diagnosed in adolescents and young adults, as well as in older adults, and can require different approaches to treatment based on a patient’s age and stage of disease. These sarcomas comprise...
Dana-Farber Cancer Institute, CPDC at McMaster University Join to Speed Cancer Research With Molecular Probes
Dana-Farber Cancer Institute and the Centre for Probe Development and Commercialization (CPDC) at McMaster University in Hamilton, Ontario, Canada, will work together to create novel molecular probes for noninvasive imaging in cancer research, drug development, and patient care. The two leading...
Cardio-oncology in the Geriatric Patient
As cancer therapies improve and the population as a whole increases, there are rising numbers of elderly patients with cancer. More than half of patients newly diagnosed with cancer are aged 65 years or older.1 In January 2012, it was estimated that more than 8 million cancer survivors were over...
Use Social Media to Stay Up-to-Date on New Patient Materials From Cancer.Net
Encourage your patients to use social media for details on the newest resources available on Cancer.Net. It is easier than ever for patients to get the latest cancer information on their computer or mobile device by subscribing to the Cancer.Net Blog at www.cancer.net/blog or on Cancer.Net’s...
As More Biosimilars Move Toward U.S. Market, Questions Remain About Cost Savings and Uptake by Physicians and Patients
The U.S. Food and Drug Administration (FDA) approved its first biosimilar drug, filgrastim-sndz (Zarxio), in 2015, allowing it to compete with the granulocyte colony-stimulating factor filgrastim (Neupogen) to treat neutropenia in chemotherapy patients. So far, filgrastim-sndz is the only...
Ellen and Gary Davis Immune Monitoring Core Established at Weill Cornell Medicine
With the goal of advancing a powerful cancer treatment strategy that uses immune cells to fight the disease, benefactors Ellen and Gary Davis have made a $2 million gift to Weill Cornell Medicine to drive ongoing research in immunotherapy, the institution announced. This gift will launch the Ellen...
FDA Grants Accelerated Approval to Olaratumab for Treatment of Advanced Soft-Tissue Sarcoma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin to treat adults with certain types of soft-tissue sarcoma. Olaratumab is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment...
Vaccines May Boost Immune Responsiveness of Pancreatic Tumors
Pancreatic cancer has been notably unresponsive to immunotherapeutic approaches, but a Stand Up 2 Cancer Dream Team believes their research can change that. Team co-leader Elizabeth Jaffee, MD, Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, ...
Combination Strategies Harness the Power of the Oncolytic Virus Talimogene Laherparepvec
The injectable oncolytic immunotherapy talimogene laherparepvec (also known as T-VEC, Imlygic) may become a valuable component of combination immunotherapy approaches in melanoma, a strategy believed to help overcome resistance of tumors to single-agent immunotherapies. “[Talimogene laherparepvec] ...
Concerns About Safety of Generic Oncology Drugs Made in Developing Countries
In a Lancet Oncology article, Yang et al examined clinical, policy, safety, and regulatory considerations for generic oncology drugs focusing on the United States, Canada, European Union (EU), Japan, China, and India. Available data do not identify safety concerns in the United States, Canada, EU,...
KEYNOTE-045 Trial Finds Pembrolizumab Improves Survival Over Chemotherapy in Advanced Urothelial Cancer
The phase III KEYNOTE-045 trial, investigating the use of the anti–PD-1 (programmed cell death protein 1) therapy pembrolizumab (Keytruda) in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival, according to a news release issued by Merck. In...
Expert Point of View: Jean-Charles Soria, MD, PhD
A number of lung cancer specialists were anxious to comment on the positive findings of KEYNOTE-024 and were equally perplexed about the negative results of CheckMate-026. All agreed that the overall survival benefit makes pembrolizumab (Keytruda) a game-changer for the first-line treatment of...
7 Substances Added to HHS 14th Report on Carcinogens
The release of the U.S. Department of Health and Human Services (HHS) 14th Report on Carcinogens on November 3, 2016, included 7 newly reviewed substances, bringing the cumulative total to 248 listings. The chemical trichloroethylene (TCE), the metallic element cobalt, and cobalt compounds...
Introduction
As expensive cancer biologics move off patent, biosimilar products are coming on board. These are highly similar versions of licensed biologics that demonstrate near-fingerprint identity to their reference products in terms of structure and potency. Biosimilars represent a major opportunity for...
Phase III Study of Sunitinib Is First to Show Benefit in Adjuvant Setting for Treatment of Renal Cell Carcinoma
Sunitinib (Sutent) improved disease-free survival by more than 1 year when used as adjuvant treatment for high-risk locoregional renal cell carcinoma following nephrectomy, but with the cost of toxicity. S-TRAC is the first phase III trial showing a benefit for adjuvant therapy in renal cell...
Putting Patients First: My Journey in Advocacy
When I lost my only sister to breast cancer in 1986, patients like her had devastatingly few choices. Over the intervening decades, sustained commitment to biomedical research at the National Institutes of Health (NIH) and major technologic advances have led to transformative changes in cancer...
New Data Suggest Changes Needed to Guidelines for Determining Prognosis in Patients With Thyroid Cancer
A study from the Duke Cancer Institute (DCI) has found a lack of statistical evidence to support the current practice of treating thyroid cancer patients under age 45 differently from those 45 and older. The study, published recently by Adam et al in the Journal of Clinical Oncology,...
How ASCO Is Preparing Members for MACRA
On October 14, 2016, the Centers for Medicare & Medicaid Services (CMS) announced its final policy on what physicians need to do to begin implementing the Quality Payment Program outlined in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The Quality Payment Program is a...
Study Raises Concerns About Timely Follow-up to Positive Mammogram for the Uninsured
A study by University of North Carolina (UNC) Lineberger Comprehensive Cancer Center researchers has found that younger, uninsured women in North Carolina had higher odds of missing a 60-day window for getting follow-up after an abnormal mammogram, even though research underscores the importance of ...
Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit From Olaparib Treatment in BRCA-Mutated Metastatic Ovarian Cancer
Positive results were announced on October 26, 2016, from the phase III SOLO-2 trial, designed to determine the efficacy of olaparib (Lynparza) tablets (300 mg twice daily) as a monotherapy for the maintenance treatment of platinum-sensitive, BRCA-mutated relapsed ovarian cancer. Results from the...
Breast Cancer Hormonal Therapy Persistence and Adherence Better in Black, Hispanic, and White Women With vs Without Medicare D Prescription Subsidies
In a study reported in the Journal of Clinical Oncology, Biggers et al found that persistence and adherence with hormonal therapy for breast cancer were greater among black, Hispanic, and white women with vs without low-income prescription subsidies in Medicare Part D. The study involved 25,111...
Effect of Patient Age on Outcomes in Breast Reconstruction
The most comprehensive study of its kind to date found that older women enjoy the same benefits from breast reconstruction following mastectomy for breast cancer as younger women, without a significant increase in the risk for complications. As with patients across all age groups, the benefits of...
Potential Link Between Androgen-Deprivation Therapy for Prostate Cancer and Risk for Dementia
In a single-center analysis reported in JAMA Oncology, Nead et al found that the use of androgen-deprivation therapy for prostate cancer was associated with an increased risk for dementia. The study involved electronic medical record data from the Stanford University Health System from 1994 to...
Proportion of Cancer Deaths From Smoking Varies Across States and Is Highest in the South
Although smoking prevalence in the U.S. has declined by more than half since 1965, nearly 40 million adults still smoke cigarettes, resulting in about 167,133 cancer deaths in 2014, according to a study by the American Cancer Society. The study investigated cancer deaths among adults 35 and older...
Presence of Oral Bacterium in Esophageal Cancer Samples Associated With Shorter Patient Survival
Among Japanese patients with esophageal cancer, those whose cancer tested positive for DNA from the bacterium Fusobacterium nucleatum had shorter cancer-specific survival compared with those whose cancer had no DNA from the bacterium, according to study results published by Yamamura et al in...
Proton Pump Inhibitors Seem to Reduce the Efficacy of Capecitabine in Advanced Gastroesophageal Cancer
In a secondary analysis of a clinical trial reported in JAMA Oncology, Chu et al found that use of proton pump inhibitors (gastric acid suppressants) reduced the effectiveness of oral capecitabine in patients with advanced gastroesophageal cancer. The study involved analysis of the effect of...
